Drugs / Subunit recombinant vaccine for the prevention of coronavirus infection
Subunit recombinant vaccine for the prevention of coronavirus infection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05156723 | Jul → Aug 2021 | COVID-19, immunodeficiency disease, respiratory tract infectious disorder | St. Petersburg Research Institute of Vaccines and Sera | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Subunit recombinant vaccine for the prevention of coronavirus infection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156723 ↗ |
| Modality | Vaccine | “Trial product is subunit recombinant vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus.” NCT05156723 ↗ |
| Route | Intramuscular | “solution for intramuscular injection, 0.5 ml” NCT05156723 ↗ |